elotuzumab
Showing 1 - 25 of 67
Multiple Myeloma Trial in Charlotte (Elotuzumab)
Active, not recruiting
- Multiple Myeloma
- Elotuzumab
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 24, 2023
Multiple Myeloma Trial in New York (Iberdomide, Elotuzumab, Dexamethasone)
Recruiting
- Multiple Myeloma
- Iberdomide
- +2 more
-
New York, New YorkIcahn School of Medicine
Jan 20, 2023
Multiple Myeloma Trial in New Haven (Elotuzumab, Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Elotuzumab
- Belantamab mafodotin
-
New Haven, ConnecticutYale New Haven Hospital
Aug 15, 2022
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
IgG4 Related Disease, IgG4-RD Trial in Atlanta, Boston, Rochester (elotuzumab, for elotuzumab, methylprednisolone)
Recruiting
- IgG4 Related Disease
- IgG4-RD
- elotuzumab
- +6 more
-
Atlanta, Georgia
- +2 more
Jul 13, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- (no location specified)
Apr 27, 2022
Multiple Myeloma Trial (Elotuzumab)
No longer available
- Multiple Myeloma
- Elotuzumab
- (no location specified)
Nov 17, 2021
Multiple Myeloma Trial in Milwaukee (Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide)
Recruiting
- Multiple Myeloma
- Isatuximab (for run-in portion)
- +4 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Feb 18, 2022
Plasma Cell Leukemia, Plasma Cell Myeloma Trial in Houston (procedure, biological, other, drug)
Active, not recruiting
- Plasma Cell Leukemia
- Plasma Cell Myeloma
- Autologous Hematopoietic Stem Cell Transplantation
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Multiple Myeloma in Relapse Trial in Finland, Sweden (Carfilzomib for Inj 60 milligram (MG), Elotuzumab 400 MG, Dexamethasone)
Active, not recruiting
- Multiple Myeloma in Relapse
- Carfilzomib for Inj 60 milligram (MG)
- +2 more
-
Helsinki, Finland
- +7 more
Mar 14, 2022
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma Trial in Houston (biological, drug, other)
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- Plasma Cell Myeloma
- Elotuzumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 1, 2023
Multiple Myeloma Trial in Chicago, Evanston, Ann Arbor (Elotuzumab, Carfilzomib, Lenalidomide)
Active, not recruiting
- Multiple Myeloma
- Elotuzumab
- +3 more
-
Chicago, Illinois
- +2 more
Nov 12, 2021
Multiple Myeloma Trial in Nagoya-shi, Shibukawa-shi, Osaka-shi (Elotuzumab, Lenalidomide, Dexamethasone)
No longer available
- Multiple Myeloma
- Elotuzumab
- +2 more
-
Nagoya-shi, Aichi, Japan
- +3 more
Nov 17, 2021
Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Elotuzumab
- +3 more
-
Boston, Massachusetts
- +5 more
Oct 28, 2021
Multiple Myeloma in Relapse Trial in Denver, Saint Louis, Toronto (Elotuzumab, Pomalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma in Relapse
- Elotuzumab
- +2 more
-
Denver, Colorado
- +2 more
Oct 14, 2021
Multiple Myeloma Trial in United States (elotuzumab, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- elotuzumab
- +3 more
-
Denver, Colorado
- +5 more
Oct 25, 2021
Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Carfilzomib)
Terminated
- Multiple Myeloma
- Elotuzumab
- +3 more
-
Encinitas, California
- +5 more
Mar 15, 2022
Smoldering Myeloma, Smoldering Multiple Myeloma Trial in United States (Elotuzumab, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Myeloma
- Smoldering Multiple Myeloma
- Elotuzumab
- +2 more
-
Denver, Colorado
- +8 more
Nov 1, 2021
Empliciti in Korean Patients With Multiple Myeloma
Withdrawn
- Multiple Myeloma
- Non-Interventional
-
Seoul, Korea, Republic ofLocal Institution
May 24, 2022
Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)
Suspended
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Oct 18, 2021
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary
Recruiting
- Myelofibrosis Transformation in Essential Thrombocythemia
- +2 more
- Elotuzumab
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Feb 17, 2021